How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Sell
32
HCM Quote, Financials, Valuation and Earnings
Last price:
$14.92
Seasonality move
:
0.42%
Day range:
$15.05 - $15.25
52-week range:
$11.51 - $19.50
Dividend yield:
0%
P/E ratio:
4.92x
P/S ratio:
4.41x
P/B ratio:
2.66x
Volume:
13.4K
Avg. volume:
47.7K
1-year change:
11.8%
Market cap:
$2.6B
Revenue:
$630.5M
EPS (TTM):
$2.66
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
HCM
HUTCHMED (China) Ltd.
|
-- | -- | -- | -- | $21.10 |
|
HKPD
Cellyan Biotechnology Ltd.
|
-- | -- | -- | -- | -- |
|
PRE
Prenetics Global Ltd.
|
$38.3M | -- | 265.18% | -- | $26.00 |
|
RGC
Regencell Bioscience Holdings Ltd.
|
-- | -- | -- | -- | -- |
|
SBHMY
Sino Biopharmaceutical Ltd.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
HCM
HUTCHMED (China) Ltd.
|
$15.25 | $21.10 | $2.6B | 4.92x | $0.00 | 0% | 4.41x |
|
HKPD
Cellyan Biotechnology Ltd.
|
$0.80 | -- | $8.8M | 8.18x | $0.00 | 0% | 0.75x |
|
PRE
Prenetics Global Ltd.
|
$20.48 | $26.00 | $344.6M | -- | $0.00 | 0% | 3.99x |
|
RGC
Regencell Bioscience Holdings Ltd.
|
$27.90 | -- | $13.8B | -- | $0.00 | 0% | -- |
|
SBHMY
Sino Biopharmaceutical Ltd.
|
$17.65 | -- | $15.8B | 31.84x | $0.13 | 1.3% | 3.75x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
HCM
HUTCHMED (China) Ltd.
|
7.07% | 0.158 | -- | 4.41x |
|
HKPD
Cellyan Biotechnology Ltd.
|
-- | 0.000 | -- | -- |
|
PRE
Prenetics Global Ltd.
|
1.29% | 5.284 | 1.18% | 1.01x |
|
RGC
Regencell Bioscience Holdings Ltd.
|
-- | 18.151 | -- | -- |
|
SBHMY
Sino Biopharmaceutical Ltd.
|
23.1% | -0.664 | -- | 1.14x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
HCM
HUTCHMED (China) Ltd.
|
-- | -- | 46.32% | 50.64% | -- | -- |
|
HKPD
Cellyan Biotechnology Ltd.
|
-- | -- | -- | -- | -- | -- |
|
PRE
Prenetics Global Ltd.
|
$14M | -$6.6M | -26.04% | -26.74% | -27.85% | -- |
|
RGC
Regencell Bioscience Holdings Ltd.
|
-- | -- | -- | -- | -- | -- |
|
SBHMY
Sino Biopharmaceutical Ltd.
|
-- | -- | 6.83% | 8.57% | -- | -- |
HUTCHMED (China) Ltd. vs. Competitors
-
Which has Higher Returns HCM or HKPD?
Cellyan Biotechnology Ltd. has a net margin of -- compared to HUTCHMED (China) Ltd.'s net margin of --. HUTCHMED (China) Ltd.'s return on equity of 50.64% beat Cellyan Biotechnology Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HCMHUTCHMED (China) Ltd.-- -- $1.3B HKPDCellyan Biotechnology Ltd.-- -- -- -
What do Analysts Say About HCM or HKPD?
HUTCHMED (China) Ltd. has a consensus price target of $21.10, signalling upside risk potential of 38.35%. On the other hand Cellyan Biotechnology Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that HUTCHMED (China) Ltd. has higher upside potential than Cellyan Biotechnology Ltd., analysts believe HUTCHMED (China) Ltd. is more attractive than Cellyan Biotechnology Ltd..
Company Buy Ratings Hold Ratings Sell Ratings HCMHUTCHMED (China) Ltd.9 2 1 HKPDCellyan Biotechnology Ltd.0 0 0 -
Is HCM or HKPD More Risky?
HUTCHMED (China) Ltd. has a beta of 0.418, which suggesting that the stock is 58.206% less volatile than S&P 500. In comparison Cellyan Biotechnology Ltd. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock HCM or HKPD?
HUTCHMED (China) Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cellyan Biotechnology Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. HUTCHMED (China) Ltd. pays -- of its earnings as a dividend. Cellyan Biotechnology Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HCM or HKPD?
HUTCHMED (China) Ltd. quarterly revenues are --, which are smaller than Cellyan Biotechnology Ltd. quarterly revenues of --. HUTCHMED (China) Ltd.'s net income of -- is lower than Cellyan Biotechnology Ltd.'s net income of --. Notably, HUTCHMED (China) Ltd.'s price-to-earnings ratio is 4.92x while Cellyan Biotechnology Ltd.'s PE ratio is 8.18x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HUTCHMED (China) Ltd. is 4.41x versus 0.75x for Cellyan Biotechnology Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HCMHUTCHMED (China) Ltd.4.41x 4.92x -- -- HKPDCellyan Biotechnology Ltd.0.75x 8.18x -- --
-
Which has Higher Returns HCM or PRE?
Prenetics Global Ltd. has a net margin of -- compared to HUTCHMED (China) Ltd.'s net margin of -28.82%. HUTCHMED (China) Ltd.'s return on equity of 50.64% beat Prenetics Global Ltd.'s return on equity of -26.74%.
Company Gross Margin Earnings Per Share Invested Capital HCMHUTCHMED (China) Ltd.-- -- $1.3B PREPrenetics Global Ltd.59.54% -$0.53 $163.3M -
What do Analysts Say About HCM or PRE?
HUTCHMED (China) Ltd. has a consensus price target of $21.10, signalling upside risk potential of 38.35%. On the other hand Prenetics Global Ltd. has an analysts' consensus of $26.00 which suggests that it could grow by 51.37%. Given that Prenetics Global Ltd. has higher upside potential than HUTCHMED (China) Ltd., analysts believe Prenetics Global Ltd. is more attractive than HUTCHMED (China) Ltd..
Company Buy Ratings Hold Ratings Sell Ratings HCMHUTCHMED (China) Ltd.9 2 1 PREPrenetics Global Ltd.1 0 0 -
Is HCM or PRE More Risky?
HUTCHMED (China) Ltd. has a beta of 0.418, which suggesting that the stock is 58.206% less volatile than S&P 500. In comparison Prenetics Global Ltd. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock HCM or PRE?
HUTCHMED (China) Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Prenetics Global Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. HUTCHMED (China) Ltd. pays -- of its earnings as a dividend. Prenetics Global Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HCM or PRE?
HUTCHMED (China) Ltd. quarterly revenues are --, which are smaller than Prenetics Global Ltd. quarterly revenues of $23.6M. HUTCHMED (China) Ltd.'s net income of -- is lower than Prenetics Global Ltd.'s net income of -$6.8M. Notably, HUTCHMED (China) Ltd.'s price-to-earnings ratio is 4.92x while Prenetics Global Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HUTCHMED (China) Ltd. is 4.41x versus 3.99x for Prenetics Global Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HCMHUTCHMED (China) Ltd.4.41x 4.92x -- -- PREPrenetics Global Ltd.3.99x -- $23.6M -$6.8M
-
Which has Higher Returns HCM or RGC?
Regencell Bioscience Holdings Ltd. has a net margin of -- compared to HUTCHMED (China) Ltd.'s net margin of --. HUTCHMED (China) Ltd.'s return on equity of 50.64% beat Regencell Bioscience Holdings Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HCMHUTCHMED (China) Ltd.-- -- $1.3B RGCRegencell Bioscience Holdings Ltd.-- -- -- -
What do Analysts Say About HCM or RGC?
HUTCHMED (China) Ltd. has a consensus price target of $21.10, signalling upside risk potential of 38.35%. On the other hand Regencell Bioscience Holdings Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that HUTCHMED (China) Ltd. has higher upside potential than Regencell Bioscience Holdings Ltd., analysts believe HUTCHMED (China) Ltd. is more attractive than Regencell Bioscience Holdings Ltd..
Company Buy Ratings Hold Ratings Sell Ratings HCMHUTCHMED (China) Ltd.9 2 1 RGCRegencell Bioscience Holdings Ltd.0 0 0 -
Is HCM or RGC More Risky?
HUTCHMED (China) Ltd. has a beta of 0.418, which suggesting that the stock is 58.206% less volatile than S&P 500. In comparison Regencell Bioscience Holdings Ltd. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock HCM or RGC?
HUTCHMED (China) Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regencell Bioscience Holdings Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. HUTCHMED (China) Ltd. pays -- of its earnings as a dividend. Regencell Bioscience Holdings Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HCM or RGC?
HUTCHMED (China) Ltd. quarterly revenues are --, which are smaller than Regencell Bioscience Holdings Ltd. quarterly revenues of --. HUTCHMED (China) Ltd.'s net income of -- is lower than Regencell Bioscience Holdings Ltd.'s net income of --. Notably, HUTCHMED (China) Ltd.'s price-to-earnings ratio is 4.92x while Regencell Bioscience Holdings Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HUTCHMED (China) Ltd. is 4.41x versus -- for Regencell Bioscience Holdings Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HCMHUTCHMED (China) Ltd.4.41x 4.92x -- -- RGCRegencell Bioscience Holdings Ltd.-- -- -- --
-
Which has Higher Returns HCM or SBHMY?
Sino Biopharmaceutical Ltd. has a net margin of -- compared to HUTCHMED (China) Ltd.'s net margin of --. HUTCHMED (China) Ltd.'s return on equity of 50.64% beat Sino Biopharmaceutical Ltd.'s return on equity of 8.57%.
Company Gross Margin Earnings Per Share Invested Capital HCMHUTCHMED (China) Ltd.-- -- $1.3B SBHMYSino Biopharmaceutical Ltd.-- -- $7.2B -
What do Analysts Say About HCM or SBHMY?
HUTCHMED (China) Ltd. has a consensus price target of $21.10, signalling upside risk potential of 38.35%. On the other hand Sino Biopharmaceutical Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that HUTCHMED (China) Ltd. has higher upside potential than Sino Biopharmaceutical Ltd., analysts believe HUTCHMED (China) Ltd. is more attractive than Sino Biopharmaceutical Ltd..
Company Buy Ratings Hold Ratings Sell Ratings HCMHUTCHMED (China) Ltd.9 2 1 SBHMYSino Biopharmaceutical Ltd.0 0 0 -
Is HCM or SBHMY More Risky?
HUTCHMED (China) Ltd. has a beta of 0.418, which suggesting that the stock is 58.206% less volatile than S&P 500. In comparison Sino Biopharmaceutical Ltd. has a beta of 0.590, suggesting its less volatile than the S&P 500 by 40.969%.
-
Which is a Better Dividend Stock HCM or SBHMY?
HUTCHMED (China) Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sino Biopharmaceutical Ltd. offers a yield of 1.3% to investors and pays a quarterly dividend of $0.13 per share. HUTCHMED (China) Ltd. pays -- of its earnings as a dividend. Sino Biopharmaceutical Ltd. pays out 55.99% of its earnings as a dividend. Sino Biopharmaceutical Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios HCM or SBHMY?
HUTCHMED (China) Ltd. quarterly revenues are --, which are smaller than Sino Biopharmaceutical Ltd. quarterly revenues of --. HUTCHMED (China) Ltd.'s net income of -- is lower than Sino Biopharmaceutical Ltd.'s net income of --. Notably, HUTCHMED (China) Ltd.'s price-to-earnings ratio is 4.92x while Sino Biopharmaceutical Ltd.'s PE ratio is 31.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HUTCHMED (China) Ltd. is 4.41x versus 3.75x for Sino Biopharmaceutical Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HCMHUTCHMED (China) Ltd.4.41x 4.92x -- -- SBHMYSino Biopharmaceutical Ltd.3.75x 31.84x -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.7T
P/E Ratio: 66x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Alerts
Buy
78
GDXU alert for Jan 30
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 38.85% over the past day.
Buy
67
PFSI alert for Jan 30
PennyMac Financial Services, Inc. [PFSI] is down 33.21% over the past day.
Buy
88
JNUG alert for Jan 30
Direxion Daily Junior Gold Miners Idx Bull 2X Shs [JNUG] is down 26.98% over the past day.
